Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...
An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...
Looking to one-up early stage entries in harnessing CRISPR technology, 2-year-old KSQ Therapeutics burst onto the biopharma scene with $76 million across two financing rounds and an aspiration to ...
The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback